贝伐株单抗联合化疗在HER2阴性进展期乳腺癌治疗中的疗效和安全性分析

摘要

Objective To observe the efficacy and safety of bevacizumab (BV) in combination with chemotherapy in the treatment for HER2 negative advanced breast cancer (ABC). Method The clinical data of 15 patients with ad-vanced disease who were treated with BV were retrospectively analyzed; the response rate and adverse reactions were evaluated as per RECIST 1.1 and NCI CTCAE, respectively, and a bimonthly evaluation was conducted for efficacy, with the primary endpoints being PFS; and adverse events were recorded in each cycle. Result For the 15 patients, the median PFS was 4 months; there were 4 cases that had more than 10 cycles of BV treatment, another 3 cases had more than 6 cycles, while the remaining 8 cases had less than 4 cycles of treatment. All patients were evaluable for efficacy, in which there were 5 cases (33.33%) of PR (including 4 cases of chest wall metastasis), 5 cases of SD (33.33%), and 5 cases of PD (33.33%); The most common adverse events was hypertension in 4, minor epistaxis in 3, proteinuria in 2, anemia in 2, and thrombocytopenia in 2, and were recovered after symptomatic treatment, and there were 4 patients discontinued the treatment. Conclusion As a second line (and above) regimen, bevacizumab combined with chemotherapy was effective and well tolerated, especially in patients with chest wall metastasis.%目的：观察贝伐珠单抗（BV）联合化疗治疗HER2阴性进展期乳腺癌的疗效和安全性。方法回顾性分析接受贝伐株单抗治疗的15例进展期乳腺癌患者的临床资料，按照实体肿瘤疗效评价标准（RECIST 1.1）和美国国立癌症研究所不良反应事件通用术语标准评价疗效和不良反应，每2个月评估疗效，主要观察终点是无进展生存期（progression free survival，PFS），每个周期评价不良反应。结果15例患者的中位PFS为4个月；治疗10个周期以上的患者为4例，6个周期以上者3例，其余8例均不足4个周期；15例患者均可评价疗效，5例（33.33%）PR中4例伴胸壁转移；5例SD（33.33%），5例PD（33.33%）；主要不良反应为高血压4例、少量鼻出血3例、蛋白尿2例、贫血2例、血小板减少2例，经对症治疗后均好转，4例停药。结论贝伐珠单抗联合化疗作为二线及以上方案治疗进展期乳腺癌仍有一定疗效，对于伴胸壁转移的患者疗效尤其显著，不良反应可耐受。